SCHEMBL6473902

SCHEMBL6473902

CCCS(=O)(=O)NCCc1ccc(-c2ccc(OC(C)CNS(=O)(=O)CCC)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 4/20 0.41
ADRB2 P07550 1/20 0.41
ADRB1 P08588 1/20 0.41
ADRB3 P13945 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA5A P35218 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
TP53 P04637 1/20 0.40
KDM4E B2RXH2 2/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ACACB O00763 2/20 0.39
ACACA Q13085 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6473271 0.94 GRIA4 (0.49) GRIA4ADRB2ADRB1ADRB3CA12
SCHEMBL6473739 0.90 CA1 (0.44) GRIA4ADRB2ADRB1ADRB3CA12
SCHEMBL6482324 0.90 GRIA4 (0.46) GRIA4CA12CA2TP53KDM4E
SCHEMBL6766134 0.89 MEN1 (0.42) GRIA4ADRB2ADRB1ADRB3CA12
SCHEMBL6482281 0.89 ACACB (0.50) ADRB2ADRB1ADRB3KDM4EALDH1A1
Hydrochloric Acid SCHEMBL6480376 0.88 MAOB (0.45) GRIA4ADRB2ADRB1ADRB3CA12
SCHEMBL6481831 0.88 GAA (0.40) ADRB2ADRB1ADRB3CA12CA1
SCHEMBL6475845 0.88 GRIA4 (0.41) GRIA4CA1CA2TP53KDM4E
Hydrochloric Acid SCHEMBL6475280 0.85 GRIA4 (0.40) GRIA4ADRB2ADRB1ADRB3CA1
SCHEMBL6475297 0.85 GRIA4 (0.48) GRIA4ALDH1A1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US claimed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US claimed
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO claimed
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US disclosed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225266-A1 Sulfonamide derivatives GRIN2A, GRM2, GRIA2 GRIA4 6/4885ADRB2 1991/4885ADRB1 2822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.